TACKLING medicines shortages and developing effective strategies to strengthen security of supply will remain key focuses for the 2021-22 Financial Year, the Generic and Biosimilar Medicines Association (GBMA) believes.
Announcing the appointment of Fresenius Kabi Senior Vice President, Juan Villar, as a new Board member, GMBA Independent Chair and former Commonwealth Department of Health Secretary, Jane Halton, said it was working to protect Australian patients from medicines shortages triggered by disruptions to global supply chains.
"With patients our absolute focus, we are looking forward to working closely with the Government on developing smart policies that allows us to maintain the delivery of high value care to all patients, through the secure supply of high quality, affordable medicines," Halton said.
Villar said GBMA's "main focus to prioritise the needs of patients and protect the medicines supply chain" aligned with Fresenius Kabi's corporate philosophy.
"We also need to ensure taxpayers reap the rewards of policies that drive a greater update of generic and biosimilar medicines in Australia," he added.
GMBA CEO, Marnie Peterson, thanked outgoing board member, Southern Cross Pharma Managing Director, Dr Neill Stacey, for his contribution to the organisation.
"For more than five years, our members have benefited from Neill's wisdom and experience as a board member," she said.
"Always generous with his time and knowledge, we know Neill will continue to help us positively shape the dynamic medicine policy landscape."
The above article was sent to subscribers in Pharmacy Daily's issue from 19 May 21
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 May 21
